A cohort study comparing the expression pattern of GPR30 in endometrial tissue from breast cancer patients who received tamoxifen, or another adjuvant therapy, showed that the intensity of GPR30 expression was significantly correlated with the time between the initiation of tamoxifen treatment and the development of an endometrial abnormality. This evidence concerns the gene GPER1 and breast carcinoma.